- Widespread off-label psychopharmacology in children increases adverse reaction risk, necessitating robust pharmacovigilance and multimodal treatment frameworks.
- Therapeutic drug monitoring yields age and sex specific dose-concentration-effect relationships, enabling therapeutic reference ranges and safer dosing.
- Integration of pharmacogenetic and epigenetic research with digital tools like Kinderformularium.de and SafeMed-Kids advances individualised precision psychopharmacotherapy.
Z Kinder Jugendpsychiatr Psychother. 2026 Oct 28. doi: 10.1024/1422-4917/a001106. Online ahead of print.
ABSTRACT
Psychopharmacotherapy in Children and Adolescents – From Pharmacovigilance to Precision Medicine Abstract: Psychopharmacotherapy plays an important role in the treatment of certain child and adolescent psychiatric disorders – always as part of a multimodal treatment approach. At the same time, psychopharmacological treatment in this age group is characterized by a lack of clinical trials supporting regulatory approval, meaning that many treatments are administered “off-label”. This may come with an increased risk of adverse drug reactions (ADRs). In this context, the Pharmacovigilance and Therapeutic Drug Monitoring working group has focused for many years on the analysis and prevention of drug-related risks in child and adolescent psychiatry. The focus is on pharmacovigilance strategies designed to ensure the safety of drug therapy in children and adolescents with psychiatric disorders and, in the long term, to contribute to more precise and individualized psychopharmacotherapy. Therapeutic drug monitoring (TDM) is a central component of this effort. Because pharmacokinetic and therapeutic reference ranges have been available primarily for adults, researchers have recently begun systematically investigating dose-concentration-effect relationships in children and adolescents undergoing psychopharmacotherapy. This research has yielded important insights into age- and sex-specific aspects for the first time, enabling the definition of dose-related ranges as well as providing data for determining therapeutic reference ranges for numerous psychotropic medications. In the future, TDM studies will be supplemented with pharmacogenetic and epigenetic investigations. At the same time, digital developments are advancing, opening new possibilities for improving medication safety. Drug information systems such as Kinderformularium.de support evidence-based dosing, even for off-label use. The monitoring app “SafeMed-Kids” enables parents to systematically document efficacy, ADRs, and treatment progress. These developments have the potential to make future psychopharmacotherapy in children and adolescents more evidence-based, safer, and more individualized. The future points toward a highly personalized, multimodal therapy precisely tailored to each child’s individual biological, psychological, and social characteristics.
PMID:42949668 | DOI:10.1024/1422-4917/a001106
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

